INT229218

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.38
First Reported 2007
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.62
Pain Relevance 0.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (F8) oxidoreductase activity (F8) extracellular region (F8)
cell adhesion (F8) plasma membrane (F8)
Anatomy Link Frequency
plasma 2
F8 (Homo sapiens)
Pain Link Frequency Relevance Heat
cva 33 97.68 Very High Very High Very High
Potency 2 73.36 Quite High
Angina 4 55.60 Quite High
Central nervous system 1 28.48 Quite Low
Inflammation 2 15.76 Low Low
tolerance 7 5.00 Very Low Very Low Very Low
Lasting pain 2 5.00 Very Low Very Low Very Low
pruritus 2 5.00 Very Low Very Low Very Low
Arthritis 2 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hemorrhage 76 99.82 Very High Very High Very High
Cv General 3 Under Development 13 97.68 Very High Very High Very High
Coagulation Disorder 84 90.24 High High
Pulmonary Embolism 5 88.16 High High
Thrombosis 4 87.00 High High
Thrombosis Related Under Development 5 86.80 High High
Toxicity 1 81.20 Quite High
Pressure And Volume Under Development 4 65.76 Quite High
Osteoarthritis 6 64.04 Quite High
Ecchymosis 1 63.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Characterization of the human factor VIII gene,10 the molecular cloning of its cDNA,11 and the transfection of mammalian cells allowed the large-scale production of full-length recombinant FVIII preparations (rFVIII) and their use for human therapy.12,13 rFVIII products omit the requirement for human blood or plasma and offer freedom from viral transmission.
Negative_regulation (allowed) of Gene_expression (production) of rFVIII in plasma
1) Confidence 0.38 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835555 Disease Relevance 0.33 Pain Relevance 0
The approved route of administration for ADVATEĀ® is via intravenous bolus infusion; however, in specific clinical circumstances such as surgery or severe or life-threatening bleeding events, FVIII products are administered via continuous infusion (Batorova and Martinowitz 2002).
Negative_regulation (administered) of Gene_expression (products) of FVIII associated with hemorrhage
2) Confidence 0.37 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291300 Disease Relevance 0.18 Pain Relevance 0.06
D-Dimer and Factor VIII levels were not checked, as these tests were not routinely utilized as part of a thromboembolic workup at the time of the event.
Neg (not) Negative_regulation (checked) of Gene_expression (levels) of Factor VIII associated with cva
3) Confidence 0.24 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2920273 Disease Relevance 1.10 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox